Clinical trial
To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in…
NCT00432185 · Peplin, Industry · Completed
Key facts
| NCT number | NCT00432185 |
|---|---|
| Title | To Determine the Maximum Tolerated Dose Level (MTD) of PEP005 Topical Gel in Patients With sBCC |
| Official title | An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk. |
| Lead sponsor | Peplin, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Superficial Basal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | PEP005 |
| Enrollment | 117 |
| Start date | Feb 1, 2007 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | Feb 7, 2007 |
| Last update posted | Feb 15, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: